Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Boehringer Ingelheim
Mallinckrodt
Baxter
Medtronic

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Claims for Patent: 5,610,052

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 5,610,052
Title: Enzymatic RNA with activity to ras
Abstract:An enzymatic RNA molecule which cleaves mRNA associated with development or maintenance of colon carcinoma.
Inventor(s): Thompson; James D. (Boulder, CO), Draper; Kenneth G. (Boulder, CO)
Assignee: Ribozyme Pharmaceuticals Inc. (Boulder, CO)
Application Number:07/936,110
Patent Claims:1. The enzymatic RNA molecule which specifically cleaves K-ras RNA.

2. The enzymatic RNA molecule of claim 1 wherein said enzymatic RNA molecule is in a hairpin, hepatitis delta virus, group I intron or RNase P RNA motif.

3. The enzymatic RNA molecule of claim 1 which specifically cleaves the sequence shown as any of SEQ. ID. NOS. 1-26, wherein said enzymatic RNA molecule is in the hepatitis delta virus motif.

4. The enzymatic RNA molecule of claim 1 wherein said enzymatic RNA molecule is in a hammerhead motif.

5. The enzymatic RNA molecule of claim 1, which specifically cleaves the sequence shown as any of SEQ. ID. NOS. 1,4-15,17-23, 25 or 26--26, wherein said enzymatic RNA molecule is in the hammerhead motif.

6. The enzymatic RNA molecule of claim 1 wherein said enzymatic RNA molecule comprises between 5 and 23 bases complementary to said RNA.

7. The enzymatic RNA molecule of claim 1 wherein said enzymatic RNA molecule comprises between 10 and 18 bases complementary to said RNA.

8. The enzymatic RNA molecule of any one of claims 1-7 wherein the enzymatic RNA molecule comprises an 2'-O-methyl modification in at least one sugar moiety.

9. The enzymatic RNA molecule of any one of claim 1-7 or wherein said enzymatic RNA molecule comprises at least one phosphorothioate group.

10. A mammalian cell comprised of an enzymatic RNA molecule of any one of claims 1-7.

11. The cell of claim 10, wherein the cell is a human cell.

12. A mammalian cell comprised of a nucleic acid encoding the enzymatic RNA molecule of any one of claims 1-7 in a manner which allows expression of the enzymatic RNA molecule within the mammalian cell.

Details for Patent 5,610,052

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 1986-06-04 ⤷  Sign up for a Free Trial 2039-02-26
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Sign up for a Free Trial 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Colorcon
Moodys
Express Scripts
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.